IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells
US12202904B2 · kind B2 · utility
0Cited by
1References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 2023 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Feb 27, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12Rβ activity and/or IL-12Rβ expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.